Distinct mechanisms of modulation of angiotensin II type I receptor gene expression in heart and aorta

Hypertension

Volumn 29, Issue 5, 1997, Pages 1104-1108

  Wang, Donna H ^a   Yao, Aqing ^a   Zhao, Huawei ^a   DiPette, Donald J ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

angiotensin II; aorta; captopril; heart; hypertension; receptors; reduced renal mass

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; COMPLEMENTARY DNA; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HYPERTENSION; KIDNEY MASS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA;

EID: 0030951302     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.5.1104     Document Type: Article

References (19)

1. Wang DH, Prewitt RL. Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension. 1990; 15:68-77.
2. Wang DH, Prewitt RL. Longitudinal study of captopril on aortic and arteriolar development in normotensive rats. Am J Physiol. 1991;260:H1959-H1965.
3. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int. 1992;42:46-55.
4. Nakamura F, Nagano M, Higaki J, Higashimori K, Morishita R, Mikami H, Ogihara T. The angiotensin-converting enzyme inhibitor, perindopril, prevents cardiac hypertrophy in low-renin hypertension. Clin Exp Pharmacol Physiol. 1993;20:135-140.
5. Brown L, Sernia C. Angiotensin receptors in cardiovascular diseases. Clin Exp Pharmacol Physiol. 1994;21:811-818.
6. Du Y, Yao A, Guo D, Inagami T, Wang DH. Differential regulation of angiotensin II receptor subtypes in rat kidney by low dietary sodium. Hypertension. 1995;25:872-877.
7. Llorens-Cortes C, Greenberg B, Huang H, Corvol P. Tissular expression and regulation of type 1 angiotensin II receptor subtypes by quantitative reverse transcriptase-polymerase chain reaction analysis. Hypertension. 1994;24:538-548.
8. Wang DH, Du Y. Distinct mechanisms of upregulation of type 1 angiotensin II receptor gene expression in kidney and adrenal gland. Hypertension. 1995;26:1134-1137.
9. DiPette DJ, Waeber B, Volicer L, Chao P, Gavras I, Gavras H, Brunner H. Salt-induced hypertension in chronic renal failure: evidence for a neurogenic mechanism. Life Sci. 1983;32:733-740.
10. Kanagy NL, Fink GD. Losartan prevents salt-induced hypertension in reduced renal mass rats. J Pharmacol Exp Ther. 1992;265: 1131-1136.
11. Pamnani MB, Chen S, Bryant HJ, Schooley JF, Haddy FJ. Effect of increased dietary calcium on the development of reduced renal mass saline hypertension in rats. J Am Coll Nutr. 1990;9:35-43.
12. Gavras I, Mulinari R, Gavras H. Renin-angiotensin and vasopressin in the development of salt-induced hypertension. J Hypertens. 1988; 6:999-1002.
13. Iwai N, Yamano Y, Chaki S, Konishi F, Bardan S, Tibbetts C, Sasaki K, Hasegawa M, Inagami T. Rat angiotensin II receptor: cDNA sequence and regulation of the gene expression. Biochem Biophys Res Commun. 1991;177:299-304.
14. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
15. Gunther S, Gimbrone MA, Alexander RW. Regulation by angiotensin II of its receptors in resistance blood vessels. Nature. 1980; 287:230-232.
16. Suzuki J, Matsubara H, Urakami M, Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res. 1993;73:439-447.
17. Owen NE, Villereal ML. Lys-bradykinin stimulates Na+ influx and DNA synthesis in cultured human fibroblasts. Cell. 1983;32: 979-985.
18. 2 and angiogenesis (41548). Proc Soc Exp Biol Med. 1983;172:214-218.
19. BenEzra D. Neovasculogenic ability of prostaglandins, growth factors and synthetic chemoattractants. Am J Ophthalmol. 1978;86: 455-461.